- Aprile 5, 2023
- Posted by: Oliver
- Categoria: Economics, Finance & accounting
Tenax Therapeutics (TENX) is scheduled to report 4th quarter earnings on 04/03/2023.
Regarding Q4 estimates, Wall Street analysts expect Tenax Therapeutics to post earnings of -$2.66 per share. Last quarter, Tenax Therapeutics beat earnings estimates, reporting EPS of -$0.11 on estimates of -$0.11. The stock fell by -11.11% the day after the last earnings release.
Year-to-date, TENX stock has fallen by -79.15%.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a pharmaceutical company, which engages in the identification, development, and commercialization of novel therapeutic products for the critical care market. Its product candidate includes Levosimendan, a calcium sensitizer activator for intravenous use in hospitalized patients with acutely decompensated heart failure. The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.